Navigation Links
FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
Date:6/16/2009

s and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the efficacy and safety of KRYSTEXXA(TM) (pegloticase), our BLA filing with the FDA, the Advisory Committee, approval of the BLA, preparation for commercialization of KRYSTEXXA, and the market for KRYSTEXXA, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may not approve our BLA for KRYSTEXXA, notwithstanding the recommendation of the Advisory Committee; any delay or failure by us in completing the development of KRYSTEXXA; varying interpretations of our clinical and CMC data by the FDA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investo
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
2. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
3. Paul Keim Appointed to febits Scientific Advisory Board
4. Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
5. Timothy I. Still Appointed CEO at Accumetrics
6. Robert Cantu Appointed Vice President of Pierpoint International
7. Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance
8. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
9. Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc.
10. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
11. Lillys Connelly Appointed to the Presidents Commission on White House Fellowships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... LONDON , June 2, 2015 ... & Inner Emotion Scanner. Scan & Read People. Analyze ... PLAY & ART Concepts, including the very first Responsive-RPG: ... ) , , , , ... to probe and truly affect your inner feelings - ...
(Date:6/2/2015)... 02, 2015 Cirrascale Corporation ... and rackmount computing and storage infrastructure for conventional ... of its high density scale-out, two-in-one video delivery ... RM1622D . The high density, two-in-one system supports ... family with Intel® Iris™ Pro graphics P6300 and ...
(Date:6/2/2015)... June 2, 2015   Y-Prime, Inc ., ... BIO Exhibition 2015 in Philadelphia ... largest biotechnology gathering, allows influential decision makers from ... they can evaluate emerging technologies such as YPrime. ... in the design, implementation and management of Interactive ...
(Date:6/2/2015)... 2015   BioClinica ® , Inc., a ... that David Peters , an accomplished senior finance ... and Chief Financial Officer (CFO) and will be joining ... more than 25 years of financial and accounting experience ... and deep knowledge in all areas of finance, accounting ...
Breaking Biology Technology:ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2BioClinica Names David Peters New Chief Financial Officer 2
... , ... ... ... ...
... ... with a Complete, Cloud-Enabled API for Developers , ... Westborough, Mass. (Vocus) March 4, 2010 -- This seminar details the fast-growing ... The free seminar will include lunch, discussion, and startup to Free Basic Account. , ...
... ... ... ... ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 2OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 3GenomeQuest Hosting Seminar at X Gen Congress In San Diego 2GenomeQuest Hosting Seminar at X Gen Congress In San Diego 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... In today,s world, we simply cannot do without lasers. We ... weld, cut, or bend car components, survey roads, monitor our ... from the Fraunhofer Institute for Applied Solid State Physics IAF ... Their quantum cascade laser a particular type of infrared ...
... 2013 -- Research!America,s 18th annual Advocacy Awards will honor ... distinguished in their commitment to advancing medicine and health. ... 2014, at the Andrew W. Mellon Auditorium in Washington, ... The 2014 Advocacy Award winners are actress Glenn ...
... Bizkaia, Bilbao Chemicals (Barakaldo 1947-1987) and Nexana (Erandio 1952-1982), ... environment with no control whatsoever. Today we have become ... by this dumping and the difficulty in achieving this ... destroy the lindane mixed with the soil. A study ...
Cached Biology News:Lasers offer an automated way to test drinking water 2Lasers offer an automated way to test drinking water 3Research!America honors leaders in medical and health research advocacy 2Research!America honors leaders in medical and health research advocacy 3Research!America honors leaders in medical and health research advocacy 4A fresh solution for the lindane problem 2A fresh solution for the lindane problem 3
...
... Ascent is the first nephelometer ... microplates. Nepheloskan measures light scattering ... for particle quantification. This makes ... in drug discovery, immunoprecipitation, and ...
... Source: Streptomycin verticillus USBio Analyzed PRODUCT SPECIFICATIONS Form: White ... tests pH (10 units/ml): 4.5 to 6.0 Loss On Drying: ... or equal to 0.1% Bleomycin Content: A 2 : 55 ... + B 2 : greater than or equal to 90% ...
... Vacuum pumps deliver critical performance for all ... control optimizes pump performance to suit all ... for convenient checking of proper oil levels ... pumps is designed to work with all ...
Biology Products: